DEF 14A

Company

Inhibikase Therapeutics, Inc.

Filed

June 20, 2024

Period of Report

August 5, 2024

Accession Number

0000950170-24-075675

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →